DelveInsight’s, “Atopic Dermatitis Competitive Landscape 2023” report provides comprehensive insights about 100+ Atopic Dermatitis companies and 110+ drugs in the Atopic Dermatitis Competitive landscape. It covers the Atopic Dermatitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Atopic Dermatitis Competitive Landscape Report

• DelveInsight’s Atopic Dermatitis report depicts a robust space with 100+ Atopic Dermatitis companies working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
• The leading Atopic Dermatitis Companies working in the market include Eli Lilly and Company, Vanda Pharmaceuticals, Arcutis Biotherapeutics, Suzhou Connect Biopharmaceuticals, Dermavant Sciences, Inc., Suzhou Zelgen Biopharmaceuticals, Reistone Biopharma, Kyowa Kirin, Cara Therapeutics, Kangstem Biotech, Arena Pharmaceuticals, Bellus Health, Tioga Pharmaceutical, BioMimetix, Botanix Pharmaceuticals, AOBiome, Aclaris Therapeutics, Asana BioSciences, Sanofi, Horizon Therapeutics, Evommune, Celgene Corporation, Allakos Inc., Bayer, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Pfizer, Ichnos Sciences, Shaperon, Pyramid Bioscience, selection, GSK, Avixgen Inc., Brexogen, Fresh Tracks Therapeutics, Yuhan Corporation, Ribon Therapeutics, Biosion, HK inno.N Corporation, NovaCell Technology Inc., Inmagene Biopharmaceuticals, and others.
• Promising Atopic Dermatitis Therapies in the various stages of development include Baricitinib, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, KP-413 Ointment, and others.
• December 2023: Sanofi announced a study of Phase 2 clinical trials for SAR444656 (KT-474). This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 3-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic therapy.
• December 2023: RAPT Therapeutics Inc. announced a study of Phase 2 clinical trials for RPT193. A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults With Moderate-to-Severe Atopic Dermatitis.

 

Request a sample and discover the recent advances in Atopic Dermatitis Drugs @ Atopic Dermatitis Competitive Landscape Report

 

The Atopic Dermatitis report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Atopic Dermatitis report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

 

Atopic Dermatitis Overview

Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children.

 

Find out more about Atopic Dermatitis Analytical Perspective: In-depth Commercial Assessment @ Atopic Dermatitis Collaboration Analysis by Companies

 

Atopic Dermatitis Companies and Therapies

• Incyte: OPZELURA
• LEO Pharma: ADTRALZA
• Cara Therapeutics Difelikefalin
• Kyowa Kirin: KHK4083
• Bayer: Zabedosertib
• Alphyn Biologics: AB-101a
• VYNE Therapeutics: FMX114
• MatriSys Bioscience: MSB-0221

 

Atopic Dermatitis Competitive Landscape: Analytical Perspective

The Atopic Dermatitis report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

Atopic dermatitis Report Assessment

• Atopic Dermatitis Company Analysis
• Atopic Dermatitis Therapeutic Assessment
• Atopic Dermatitis Pipeline Assessment
• Inactive Atopic Dermatitis Drugs assessment
• Atopic Dermatitis Unmet Needs

 

Learn more about the emerging Atopic Dermatitis Competitive Landscape @ Atopic Dermatitis Market Drivers and Barriers, Unmet Needs

 

Scope of the Atopic Dermatitis Report

• Coverage- Global
• Atopic Dermatitis Companies- Eli Lilly and Company, Vanda Pharmaceuticals, Arcutis Biotherapeutics, Suzhou Connect Biopharmaceuticals, Dermavant Sciences, Inc., Suzhou Zelgen Biopharmaceuticals, Reistone Biopharma, Kyowa Kirin, Cara Therapeutics, Kangstem Biotech, Arena Pharmaceuticals, Bellus Health, Tioga Pharmaceutical, BioMimetix, Botanix Pharmaceuticals, AOBiome, Aclaris Therapeutics, Asana BioSciences, Sanofi, Horizon Therapeutics, Evommune, Celgene Corporation, Allakos Inc., Bayer, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Pfizer, Ichnos Sciences, Shaperon, Pyramid Bioscience, selection, GSK, Avixgen Inc., Brexogen, Fresh Tracks Therapeutics, Yuhan Corporation, Ribon Therapeutics, Biosion, HK inno.N Corporation, NovaCell Technology Inc., Inmagene Biopharmaceuticals, and others.
• Atopic Dermatitis Therapies- Baricitinib, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, KP-413 Ointment, and others.
• Atopic Dermatitis Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

 

Dive deep into rich insights for new drugs for Atopic Dermatitis Product Developmental Activities, Visit @ Atopic Dermatitis Research and Development Activities

 

Table of Content

1. Introduction
2. Atopic Dermatitis Executive Summary
3. Atopic dermatitis: Overview
4. Atopic dermatitis -Analytical Perspective: In-depth Commercial Assessment
5. Atopic Dermatitis Competitive Landscape
6. Atopic Dermatitis Therapeutic Assessment
7. Atopic dermatitis: Company and Product Profiles (Marketed Therapies)
8. Incyte
9. OPZELURA
10. Atopic dermatitis: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Cara Therapeutics
13. Difelikefalin
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Bayer
17. Zabedosertib
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Merck Sharp & Dohme LLC
21. MK-6194
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Atopic dermatitis Unmet needs
29. Atopic dermatitis Market drivers and barriers
30. Appendix

 

For further information on the Atopic Dermatitis Report @ Atopic Dermatitis Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services